All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 16, 2022

European Society for Medical Oncology

Home » Topics » Conferences » European Society for Medical Oncology
  • Sep. 22, 2021

    Conference data for Sept. 22, 2021: ESMO

    New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2021, including: Aprea, Redx, Syros.
  • Sep. 22, 2021

    Conference data for Sept. 21, 2021: ESMO

    New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2021, including: Astellas, Astrazeneca, Beyondspring, Byondis, Carsgen, Cstone, Daiichi, Exelixis, Genentech, Genmab, GT, Innovent, Immunocore, Ipsen, Janssen, Merck, Mirati, Novartis, Ose, Regeneron, Sanofi, Spectrum, Verastem, Veru.
  • Sep. 21, 2021
    By Lee Landenberger

    Beyondspring NSCLC phase III hits primary endpoint but stock sags anyway

    Despite Beyondspring Pharmaceuticals Inc.’s phase III study meeting its primary and key secondary endpoints of a plinabulin/docetaxel combination in treating non-small-cell lung cancer (NSCLC), the company stock (NADAQ:BYSI) took a pounding. Shares sunk 32.9% on Sept. 20 to close at $15.36 each.
Read More

Authors

  • Anette Breindl
  • Lee Landenberger
  • Peter Winter
  • David Ho
  • Annette Boyle
More Authors
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing